__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
ILARIS is the first and only selective IL-1β inhibitor for the treatment of FMF, HIDS/MKD, TRAPS and CAPS in adults, adolescents and children aged ≥2 years.1
ILARIS mechanism of action
Image created using information from references 1, 2 and 6
*Complete response was defined as resolution of the baseline flare at day 15 (PGA score <2 plus CRP ≤10 mg/L or a reduction by ≥70% from baseline) and no new flare (PGA score ≥2 and CRP ≥30 mg/L) up to Week 16.1
†Complete response was defined as composite of PGA of autoinflammatory disease activity, and assessment of no or minimal skin disease, and CRP or SAA values <10 mg/L. PGA of disease activity was based on a composite of the following symptoms: urticarial skin rash, arthralgia, myalgia, headache/migraine, conjunctivitis and fatigue/malaise.2
Indications
ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:
- CAPS, including:
- Muckle-Wells syndrome (MWS)
- Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)
- Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash
- TRAPS
- HIDS/MKD
- FMF
- ILARIS should be given in combination with colchicine, if appropriate.
CAPS, cryopyrin-associated periodic syndromes; CRP, c-reactive protein; FMF, familial Mediterranean fever; HIDS, hyperimmunoglobulin D syndrome; IL, interleukin; MKD, mevalonate kinase deficiency; PGA, physician global assessment; SAA, serum amyloid A; TRAPS, tumour necrosis factor receptor-associated periodic syndrome.
References
- ILARIS® (canakinumab) Summary of Product Characteristics.
- Lachmann HJ et al. Arthritis Rheum 2011;63(2):314–324.
- De Benedetti F et al. N Engl J Med 2018;378:1908–1919.
- Kuemmerle-Deschner J et al. Pediatr Rheumatol 2015;13(Suppl 1):P3.
- NHS England. Clinical Commissioning Policy: Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 years and older). February 2020. Available at: https://www.england.nhs.uk/wp-content/uploads/2020/03/Canakinumab-for-tr... [Accessed July 2021].
- Lin YT et al. Autoimmun Rev 2011;10(8):482–489.